Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
YORVIPATH is designed to provide continuous exposure to released PTH over the 24-hour dosing period. It is currently approved in the European Union, U.K. and European Economic Area.ELK GROVE VILLAGE, Ill., Dec. 9, 2024 /PRNewswire/ -- Orsini has been selected by Ascendis Pharma as a specialty pharmacy partner for YORVIPATH (palopegteriparatide), an FDA-approved parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. Read the US Full Prescribing Information here.
伊利諾伊州埃爾克格羅夫村，2024年12月9日 /PRNewswire/ -- Orsini被Ascendis Pharma選爲YORVIPATH（palopegteriparatide）的專業藥房合作伙伴，該藥物是經FDA批准的甲狀旁腺激素類藥物（PTH(1-34)），用於治療成人低甲狀旁腺功能亢進症。詳細的美國處方信息請點擊此處。
Chronic hypoparathyroidism is a rare disorder that affects about 70,000 people in the U.S., caused when a patient's body produces abnormally low levels of parathyroid hormone. This leads to low calcium levels and high phosphorus levels in the blood, and those living with chronic hypoparathyroidism can experience a range of symptoms including chronic pain, muscle cramps, cataracts, bone damage and kidney stones.
慢性低甲狀旁腺功能亢進症是一種罕見疾病，影響美國約70,000人，患者體內甲狀旁腺激素產生異常低，導致血鈣水平低和血磷水平高，慢性低甲狀旁腺功能亢進症患者可以經歷一系列症狀，包括慢性疼痛、肌肉痙攣、白內障、骨損傷和腎結石。
"We're thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies."
"我們很高興將YORVIPATH添加到我們不斷增長的內分泌治療組合中。"
YORVIPATH is designed to provide continuous exposure to released PTH over the 24-hour dosing period. It is currently approved in the European Union, U.K. and European Economic Area.
YORVIPATH旨在在24小時的給藥期內提供持續的PTH暴露。該藥物目前已在歐盟、英國和歐洲經濟區獲得批准。
"We're thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies," Darin DeCarlo, Orsini's Chief Growth Officer, said. "Orsini is built to serve rare disease patients, and we're excited to partner with Ascendis to deliver this new treatment option to patients suffering from chronic hypoparathyroidism."
"我們很高興將YORVIPATH添加到我們不斷增長的內分泌治療組合中，"Orsini的首席增長官Darin DeCarlo說。"Orsini致力於服務罕見疾病患者，我們很高興與Ascendis合作，爲慢性低甲狀旁腺功能亢進症患者提供這種新治療選擇。"
About Orsini
關於奧爾西尼
Providing compassionate care since 1987, Orsini is a leader in rare disease and gene therapy pharmacy solutions, built to simplify how patients connect to advanced medicines. Through our comprehensive commercialization solutions including a nationwide specialty pharmacy, patient services hub, home infusion and nursing network, and third-party logistics provider, we work with biopharma, providers, and payors to ensure No Patient is Left Behind.
自1987年以來提供富有同情心的護理，Orsini在罕見疾病和基因治療藥品解決方案方面處於領先地位，旨在簡化患者與愛文思控股的聯繫。通過我們的全面商業化解決方案，包括全國範圍的專業藥房、患者服務中心、家庭輸注和護理網絡以及第三方物流提供商，我們與生物製藥公司、提供者和支付方合作，確保沒有患者被落下。
Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, contact Orsini at 847-734-7373 ext. 505, email us at [email protected], or visit .
Orsini獲得了醫療保健認可委員會（ACHC）、the joint委員會、URAC和NABP的認證。Orsini獲得了URAC的稀有疾病藥房卓越中心認證和ACHC的稀有疾病與孤兒藥物的特別榮譽。如需更多信息，請聯繫Orsini，電話847-734-7373，分機505，或發送電子郵件至[email protected]，或者訪問。
SOURCE Orsini
來源：Orsini
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
